Key Points
- Natera director Rowan Chapman sold 2,964 shares on June 16 at an average price of $216.78, totaling about $642,536. The sale cut Chapman's stake by nearly 49% and was made under a pre-arranged Rule 10b5-1 trading plan.
- Natera shares were up 2.9% in Thursday trading, opening at $226.44. The stock remains well above its 50-day and 200-day moving averages, with a 52-week range of $131.81 to $256.36.
- Wall Street remains broadly bullish on Natera, with a consensus “Moderate Buy” rating and an average price target of $256.53. Institutional ownership is extremely high at 99.90%, and several major firms recently increased their positions.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Rowan Chapman sold 2,964 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total value of $642,535.92. Following the sale, the director owned 3,124 shares of the company's stock, valued at approximately $677,220.72. The trade was a 48.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Natera Trading Up 2.9%
Shares of Natera stock opened at $226.44 on Thursday. The business has a 50-day moving average price of $207.35 and a two-hundred day moving average price of $215.50. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36. The company has a market cap of $32.43 billion, a P/E ratio of -138.92 and a beta of 1.56.
Hedge Funds Weigh In On Natera
Several large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its position in Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares in the last quarter. Wellington Management Group LLP lifted its position in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. State Street Corp lifted its position in Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock valued at $545,624,000 after acquiring an additional 72,087 shares in the last quarter. Franklin Resources Inc. lifted its position in Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company's stock valued at $428,987,000 after acquiring an additional 727,366 shares in the last quarter. Finally, Coatue Management LLC lifted its position in Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after acquiring an additional 2,463,008 shares in the last quarter. Institutional investors own 99.90% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on NTRA shares. Morgan Stanley decreased their price target on Natera from $265.00 to $250.00 and set an "overweight" rating for the company in a report on Tuesday, March 3rd. Evercore reiterated an "outperform" rating and set a $270.00 price target on shares of Natera in a report on Friday, May 8th. William Blair began coverage on Natera in a research note on Tuesday, April 14th. They issued an "outperform" rating for the company. Piper Sandler restated an "overweight" rating and issued a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. Finally, Wolfe Research began coverage on Natera in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $260.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and a consensus price target of $256.53.
Read Our Latest Analysis on NTRA
About Natera
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
